Patents by Inventor Remy Henri Luthringer

Remy Henri Luthringer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS OF USE OF CYCLIC AMIDE DERIVATIVES TO TREAT SCHIZOPHRENIA
    Publication number: 20220274951
    Abstract: Disclosed herein are compositions and methods for treating schizophrenia and symptoms of schizophrenia, including negative symptoms of schizophrenia.
    Type: Application
    Filed: May 16, 2022
    Publication date: September 1, 2022
    Inventors: Remy Henri LUTHRINGER, Lorenzo PELLEGRINI, Argeris N. KARABELAS
  • USE OF ROLUPERIDONE TO TREAT NEGATIVE SYMPTOMS AND DISORDERS, INCREASE NEUROPLASTICITY, AND PROMOTE NEUROPROTECTION
    Publication number: 20220096455
    Abstract: The present application relates to the use of roluperidone, i.e., Compound (I): and salts, solvates, pharmaceutical compositions, and dosage forms thereof, for use in methods of treating negative symptoms and disorders (e.g., autism disorders, amblyopia, personality disorders, traumatic brain injury), as well as increasing neuroplasticity and promoting neuroprotection in subjects in need thereof.
    Type: Application
    Filed: July 2, 2021
    Publication date: March 31, 2022
    Inventor: Remy Henri LUTHRINGER
  • Use of roluperidone to treat negative symptoms and disorders, increase neuroplasticity, and promote neuroprotection
    Patent number: 11083723
    Abstract: The present application relates to the use of roluperidone, i.e., Compound (I): and salts, solvates, pharmaceutical compositions, and dosage forms thereof, for use in methods of treating negative symptoms and disorders (e.g., autism disorders, amblyopia, personality disorders, traumatic brain injury), as well as increasing neuroplasticity and promoting neuroprotection in subjects in need thereof.
    Type: Grant
    Filed: August 21, 2019
    Date of Patent: August 10, 2021
    Assignee: Minerva Neurosciences, Inc.
    Inventor: Remy Henri Luthringer
  • METHODS OF USE OF CYCLIC AMIDE DERIVATIVES TO TREAT SIGMA RECEPTOR MEDIATED DISORDERS
    Publication number: 20210106573
    Abstract: Disclosed herein are compositions and methods for treating a sigma-2 receptor-mediated condition or disorder, including treating one or more symptoms of a sigma-2 receptor-mediated condition or disorder.
    Type: Application
    Filed: June 29, 2020
    Publication date: April 15, 2021
    Inventors: Remy Henri LUTHRINGER, Lorenzo PELLEGRINI, Argeris N. KARABELAS
  • USE OF ROLUPERIDONE TO TREAT NEGATIVE SYMPTOMS AND DISORDERS, INCREASE NEUROPLASTICITY, AND PROMOTE NEUROPROTECTION
    Publication number: 20200061046
    Abstract: The present application relates to the use of roluperidone, i.e., Compound (I): and salts, solvates, pharmaceutical compositions, and dosage forms thereof, for use in methods of treating negative symptoms and disorders (e.g., autism disorders, amblyopia, personality disorders, traumatic brain injury), as well as increasing neuroplasticity and promoting neuroprotection in subjects in need thereof.
    Type: Application
    Filed: August 21, 2019
    Publication date: February 27, 2020
    Inventor: Remy Henri LUTHRINGER
  • METHODS OF USE OF CYCLIC AMIDE DERIVATIVES TO TREAT SCHIZOPHRENIA
    Publication number: 20180155318
    Abstract: Disclosed herein are compositions and methods for treating schizophrenia and symptoms of schizophrenia, including negative symptoms of schizophrenia.
    Type: Application
    Filed: July 21, 2017
    Publication date: June 7, 2018
    Inventors: Remy Henri LUTHRINGER, Lorenzo PELLEGRINI, Argeris N. KARABELAS
  • Methods of use of cyclic amide derivatives to treat schizophrenia
    Patent number: 9732059
    Abstract: Disclosed herein are compositions and methods for treating schizophrenia and symptoms of schizophrenia, including negative symptoms of schizophrenia.
    Type: Grant
    Filed: July 20, 2011
    Date of Patent: August 15, 2017
    Assignee: Minerva Neurosciences, Inc.
    Inventors: Remy Henri Luthringer, Lorenzo Pellegrini, Argeris N. Karabelas
  • METHODS OF USE OF CYCLIC AMIDE DERIVATIVES TO TREAT SIGMA RECEPTOR MEDIATED DISORDERS
    Publication number: 20160354357
    Abstract: Disclosed herein are compositions and methods for treating a sigma-2 receptor-mediated condition or disorder, including treating one or more symptoms of a sigma-2 receptor-mediated condition or disorder.
    Type: Application
    Filed: May 24, 2016
    Publication date: December 8, 2016
    Inventors: REMY HENRI LUTHRINGER, LORENZO PELLEGRINI, ARGERIS N. KARABELAS
  • METHODS OF USE OF CYCLIC AMIDE DERIVATIVES TO TREAT SCHIZOPHRENIA
    Publication number: 20130274289
    Abstract: Disclosed herein are compositions and methods for treating schizophrenia and symptoms of schizophrenia, including negative symptoms of schizophrenia.
    Type: Application
    Filed: July 20, 2011
    Publication date: October 17, 2013
    Inventors: Remy Henri Luthringer, Lorenzo Pellegrini, Argeris N. Karabelas
  • METHODS OF USE OF CYCLIC AMIDE DERIVATIVES TO TREAT SIGMA RECEPTOR MEDIATED DISORDERS
    Publication number: 20130274290
    Abstract: Disclosed herein are compositions and methods for treating a sigma-2 receptor- mediated condition or disorder, including treating one or more symptoms of a sigma-2 receptor-mediated condition or disorder.
    Type: Application
    Filed: July 20, 2011
    Publication date: October 17, 2013
    Applicant: CYRENAIC PHARMACEUTICALS, INC.
    Inventors: Remy Henri Luthringer, Lorenzo Pellegrini, Argeris N. Karabelas